Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1 Our quality journey Quality improvement and practice-based research in neurology using the electronic medical record (EMR) consists of a stepwise.

Published byRudolph Clark Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 1 Our quality journey Quality improvement and practice-based research in neurology using the electronic medical record (EMR) consists of a stepwise."— Presentation transcript:

1 Figure 1 Our quality journey Quality improvement and practice-based research in neurology using the electronic medical record (EMR) consists of a stepwise progression from the development and implementation of structured clinical documentation support (SCD... Our quality journey Quality improvement and practice-based research in neurology using the electronic medical record (EMR) consists of a stepwise progression from the development and implementation of structured clinical documentation support (SCDS) toolkits (including note writing and electronic data capture); to enrollment reports; to data quality reports (and data cleaning); to descriptive reports of cohort characteristics; to quality improvement projects (including the creation of benchmark data and quality improvement dashboards); to the use of clinical decision support tools (to hardwire patient safety and improved outcomes); to the use of subgroup-based adaptive assignments (in support of pragmatic clinical trials and personalized medicine); to other research (e.g., biobanking of DNA and the association of genotypes with longitudinal outcomes). The EMR provides a framework for measuring and impacting the 3 dimensions of quality improvement: structure, process, and outcomes. Demetrius M. Maraganore et al. Neurol Clin Pract 2015;5: © 2015 American Academy of Neurology

Download ppt "Figure 1 Our quality journey Quality improvement and practice-based research in neurology using the electronic medical record (EMR) consists of a stepwise."

Similar presentations

Butte Lab Journal Club 16 Aug 2010 Alexander A. Morgan.

Butte Lab Journal Club 16 Aug 2010 Alexander A. Morgan.
My Own Health Report: Case Study for Pragmatic Research Marcia Ory Texas A&M Health Science Center Presentation at: CPRRN Annual Grantee Meeting October.

My Own Health Report: Case Study for Pragmatic Research Marcia Ory Texas A&M Health Science Center Presentation at: CPRRN Annual Grantee Meeting October.
CMS Physician Quality Reporting J. Marc Overhage, MD, PhD Director of Medical Informatics, Regenstrief Institute Regenstrief Professor of Medical Informatics,

CMS Physician Quality Reporting J. Marc Overhage, MD, PhD Director of Medical Informatics, Regenstrief Institute Regenstrief Professor of Medical Informatics,
HS420 Health Informatics Michele Smith, PharmD, RPh, RCph Unit Seven Data Quality Tools.

HS420 Health Informatics Michele Smith, PharmD, RPh, RCph Unit Seven Data Quality Tools.
The Holistic Approach to the Design and Meaningful Use of Electronic Health Records: A Nursing Experience Frances Beadle, MSc Health Informatics Nurse.

The Holistic Approach to the Design and Meaningful Use of Electronic Health Records: A Nursing Experience Frances Beadle, MSc Health Informatics Nurse.
1 The Holistic Approach to the Design and Meaningful Use of Electronic Health Records: A Nursing Experience Frances Beadle, MSc Health Informatics Nurse.

1 The Holistic Approach to the Design and Meaningful Use of Electronic Health Records: A Nursing Experience Frances Beadle, MSc Health Informatics Nurse.
HS420 Health Informatics Michele Smith, PharmD, RPh, RCph

HS420 Health Informatics Michele Smith, PharmD, RPh, RCph
Figure Pedigrees of the SCA42 families identified in this study

Figure Pedigrees of the SCA42 families identified in this study
Figure Flow of funds for a 340B agreement for fingolimod

Figure Flow of funds for a 340B agreement for fingolimod
Figure 1 Percentages of patients with first seizure experiencing a recurrent seizure over time This graph is based on a fixed-effect pooled percentage.

Figure 1 Percentages of patients with first seizure experiencing a recurrent seizure over time This graph is based on a fixed-effect pooled percentage.
Introduction to Electronic Health Records

Introduction to Electronic Health Records
Figure 2. Change in total PSPRS score from baseline to each study visit for all participants Change in total PSPRS score from baseline to each study visit.

Figure 2. Change in total PSPRS score from baseline to each study visit for all participants Change in total PSPRS score from baseline to each study visit.
Figure Brain MRI of the patient throughout the disease course(A) Brain MRI at the time of cerebral toxoplasmosis diagnosis (a) and after 1 month of toxoplasmosis.

Figure Brain MRI of the patient throughout the disease course(A) Brain MRI at the time of cerebral toxoplasmosis diagnosis (a) and after 1 month of toxoplasmosis.
Figure 2 FXTAS Rating Scale scores for case 1

Figure 2 FXTAS Rating Scale scores for case 1
Figure Revised Niemann-Pick disease type C (NP-C) diagnostic algorithm for the use of biomarkers and genetic testing Revised Niemann-Pick disease type.

Figure Revised Niemann-Pick disease type C (NP-C) diagnostic algorithm for the use of biomarkers and genetic testing Revised Niemann-Pick disease type.
Figure 1 Flow diagram of the assays and the samples that were evaluatedA total of 1,109 samples were initially screened at a serum dilution of 1:20 for.

Figure 1 Flow diagram of the assays and the samples that were evaluatedA total of 1,109 samples were initially screened at a serum dilution of 1:20 for.
Figure 2 Primary and secondary outcomes reported in multiple sclerosis (MS) disease-modifying therapy (DMT) clinical trials Primary and secondary outcomes.

Figure 2 Primary and secondary outcomes reported in multiple sclerosis (MS) disease-modifying therapy (DMT) clinical trials Primary and secondary outcomes.
Figure 1 Outcomes of greatest importance to selection of a multiple sclerosis (MS) disease-modifying therapy (DMT), as defined by persons with MS and panelists.

Figure 1 Outcomes of greatest importance to selection of a multiple sclerosis (MS) disease-modifying therapy (DMT), as defined by persons with MS and panelists.
Figure 2 Provider decision algorithm: Considerations in retirement discussion and recommendation Provider decision algorithm: Considerations in retirement.

Figure 2 Provider decision algorithm: Considerations in retirement discussion and recommendation Provider decision algorithm: Considerations in retirement.
Figure 1 MOR103 sequential-dose trial flowchart of study population with multiple sclerosis aPatients received 2 doses of study drug before trial withdrawal.

Figure 1 MOR103 sequential-dose trial flowchart of study population with multiple sclerosis aPatients received 2 doses of study drug before trial withdrawal.

Similar presentations

Ads by Google